Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence A Francis

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|December 17, 2019
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and durationPrudence A Francis
Breast (Edinburgh, Scotland)|May 25, 2011
Optimal adjuvant therapy for very young breast cancer patientsPrudence A Francis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Surprised by hopePrudence A Francis
Breast (Edinburgh, Scotland)|July 4, 2017
Adjuvant endocrine therapy for premenopausal women: Type and durationPrudence A Francis
Hematology/Oncology Clinics of North America|November 26, 2022
Role of Ovarian Suppression in Early Premenopausal Breast CancerPrudence A Francis
The Medical Journal of Australia|February 21, 2024
PEG-GCSF-induced aortitis in a patient with breast cancer: distinguishing between infective and immune-mediated aortitisLuigi Zolio, Prudence A Francis, Nava Ferdowsi
Breast (Edinburgh, Scotland)|December 28, 2010
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomesMadhu S Singh, Prudence A Francis, Michael Michael
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Prudence A Francis, et al.
Breast (Edinburgh, Scotland)|April 24, 2016
Are SOFT and TEXT results practice changing and how?Olivia Pagani, Meredith M Regan, Prudence A Francis
The New England Journal of Medicine|April 23, 2015
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|December 17, 2019
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and durationPrudence A Francis
Breast (Edinburgh, Scotland)|May 25, 2011
Optimal adjuvant therapy for very young breast cancer patientsPrudence A Francis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Surprised by hopePrudence A Francis
Breast (Edinburgh, Scotland)|July 4, 2017
Adjuvant endocrine therapy for premenopausal women: Type and durationPrudence A Francis
Hematology/Oncology Clinics of North America|November 26, 2022
Role of Ovarian Suppression in Early Premenopausal Breast CancerPrudence A Francis
The Medical Journal of Australia|February 21, 2024
PEG-GCSF-induced aortitis in a patient with breast cancer: distinguishing between infective and immune-mediated aortitisLuigi Zolio, Prudence A Francis, Nava Ferdowsi
Breast (Edinburgh, Scotland)|December 28, 2010
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomesMadhu S Singh, Prudence A Francis, Michael Michael
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Prudence A Francis, et al.
Breast (Edinburgh, Scotland)|April 24, 2016
Are SOFT and TEXT results practice changing and how?Olivia Pagani, Meredith M Regan, Prudence A Francis
The New England Journal of Medicine|April 23, 2015
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming
Pageof 9